Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical. | May 23, 2023
Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency which is designed to. | May 16, 2023
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA. | April 20, 2023
CAMBRIDGE, Mass., March 29, 2023 Wave Life Sciences Ltd. , a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases,. | March 29, 2023
CAMBRIDGE, Mass., May 25, 2022 Wave Life Sciences Ltd. , a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases,. | May 25, 2022